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c-Src tyrosine kinase plays a critical role in signal transduction downstream of growth factor receptors,
integrins and G protein-coupled receptors. We used stable isotope labeling with amino acids in cell
culture (SILAC) approach to identify additional substrates of c-Src tyrosine kinase in human embryonic
kidney 293T cells. We have identiﬁed 10 known substrates and interactors of c-Src and Src family kinases
along with 26 novel substrates. We have experimentally validated 4 of the novel proteins (NICE-4, RNA
binding motif 10, FUSE-binding protein 1 and TRK-fused gene) as direct substrates of c-Src using in
vitro kinase assays and cotransfection experiments. Signiﬁcantly, using a c-Src speciﬁc inhibitor, we
were also able to implicate 3 novel substrates (RNA binding motif 10, EWS1 and Bcl-2 associated
transcription factor) in PDGF signaling. Finally, to identify the exact tyrosine residues that are
phosphorylated by c-Src on the novel c-Src substrates, we designed custom peptide microarrays
containing all possible tyrosine-containing peptides (312 unique peptides) and their mutant counterparts
containing a Tyr f Phe substitution from 14 of the identiﬁed substrates. Using this platform, we
identiﬁed 34 peptides that are phosphorylated by c-Src. We have demonstrated that SILAC-based
quantitative proteomics approach is suitable for identiﬁcation of substrates of nonreceptor tyrosine
kinases and can be coupled with peptide microarrays for high-throughput identiﬁcation of substrate
phosphopeptides.
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Introduction
Most signaling pathways include protein kinases and their
substrates that serve as means to amplify signals from extra-
cellular signals and other stimuli. However, the precise con-
nectivity between protein kinases and their downstream sub-
strates has not been fully elucidated for most protein kinases.
c-Src is a classic nonreceptor tyrosine kinase that has been
implicated in regulation of cytoskeletal rearrangement and cell
adhesion networks that control cell migration, cell proliferation
and cell survival.
1 One vital step in understanding the role of
c-Src kinase in cellular transformation and signaling is sys-
tematic identiﬁcation of all of its potential cellular substrates
involved in these processes.
Recent studies based on advances in mass spectrometry-
based proteomics have provided large-scale catalogs of phos-
phorylation sites.
2–5 However, determination of kinases re-
sponsible for these phosphorylation events is not an easy task
owing to the transient interaction between kinases and their
substrates. Chemical and genetic approaches have been previ-
ously used to identify c-Src substrates. Such studies include
use of an ATP analogue that is a speciﬁc substrate for an
analogue-speciﬁc allele of v-Src,
6 screening of cDNA expression
libraries with anti-phosphotyrosine antibodies
7 and use of
mutant inducible forms of c-Src.
8 To date, several c-Src
substrates as well as interactors have been reported. Human
Protein Reference Database (HPRD)
9 provides a list of 132 c-Src
mediated phosphorylation sites in 64 known substrates along
with 204 proteins that interact with c-Src.
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in cell culture (SILAC) approach which enables identiﬁcation
of tyrosine kinase substrates based on a unique signature in
mass spectrometry experiments.
10–12 The main objective of this
work was to identify novel c-Src substrates by overexpression
of a constitutively active form of c-Src followed by enrichment
of tyrosine-phosphorylated proteins. We have identiﬁed 26
novel c-Src tyrosine kinase substrates in addition to 10 others,
which were either known Src family kinase substrates or
proteins known to associate with Src family kinases. We have
experimentally conﬁrmed 4 novel substrates, NICE-4, RNA
binding motif 10, FUSE-binding protein 1 and TRK-fused gene,
to be direct substrates of c-Src using in vitro kinase assays. We
were also able to implicate EWS1, RNA binding motif 10 and
Bcl-2 associated transcription factor in PDGF signaling using
a chemical inhibitor of c-Src. Our peptide microarray approach
led to identiﬁcation of a number of peptides that are phos-
phorylated by c-Src. To our knowledge, this is the ﬁrst reported
integrated proteomics strategy that couples cell culture, mass
spectrometry and peptide microarrays to identify tyrosine
kinase substrates.
Experimental Procedures
Chemicals and Antibodies. Stable isotope containing amino
acids,
12C6-arginine,
13C6-arginine and
13C6-
15N4-arginine, were
purchased from Cambridge Isotope Labs (Andover, MA).
Complete protease inhibitor cocktail tablets were purchased
from Roche (Indianapolis, IN), sodium orthovanadate and anti-
Flag M2 monoclonal antibody from Sigma-Aldrich Co. (St.
Louis, MO), SU6656 from EMD Biosciences, Inc. (San Diego,
CA), anti-phosphotyrosine antibodies (4G10) agarose-conjugate
and streptavidin-agarose beads from Upstate Biotechnology
(Lake Placid, NY), antiphosphotyrosine-RC20 biotin conjugate
from BD Biosciences (San Jose, CA) and PDGF-BB from
Invitrogen (Carlsbad, CA). Sequencing grade trypsin was pur-
chased from Promega (Madison, WI). Antibodies against cort-
actin were purchased from Upstate USA, Inc. (Chicago, IL),
p130CAS and EWS1 from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA), BTF from Bethyl, Inc. (Montgomery, TX), and RBM10
was from Abcam, Inc. (Cambridge, MA). Phospho-Src (Tyr416)
antibody and PhosphoScan Kit (P-Tyr-100) were purchased
from cell signaling technology (Boston, MA).
Cell Culture and Stable Isotope Labeling with Amino
Acid in Cell Culture (SILAC). Human embryonic kidney 293T
cells were grown in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) containing ‘light’, ‘medium’ or ‘heavy’ arginine supple-
mented with 10% dialyzed fetal bovine serum (FBS) plus
antibiotics. The 293T cells were adapted to growing in isotope
rich-medium supplemented with dialyzed serum prior to
initiating these experiments. In each experiment, 20 10-cm
dishes were used per condition and the cells were transfected
with 15 µg of DNA using the standard calcium phosphate
method (Invitrogen, Carlsbad, CA). Six hours after transfection,
the cells were serum-starved for 10 or 20 h. After starvation,
the cells were lysed in modiﬁed RIPA buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 0.25%
sodium deoxycholate, and 1 mM sodium orthovanadate in the
presence of protease inhibitors). Upon cell lysis, proteins lysates
were either subjected to afﬁnity puriﬁcation of tyrosine phos-
phorylated proteins
13 or peptides containing phosphotyrosine
were enriched directly from trypsin-digested cell lysates
14 using
speciﬁc antibodies against phosphotyrosine and identiﬁed by
tandem mass spectrometry.
Immunoprecipitation and Western Blotting. Light, medium
and heavy cell lysates were precleared with protein A-agarose,
mixed, and incubated with 400 µg of 4G10 monoclonal anti-
bodies coupled with agarose beads, 75 µg of biotin-conjugated
RC20 antibody, and streptavidin-agarose beads overnight at 4
°C. Precipitated immune complexes were then washed three
times with lysis buffer. Agarose beads were boiled and resolved
by 10% SDS-PAGE. The gel was silver-stained for visualizing
protein bands. Western blotting experiments were performed
using anti-phosphotyrosine antibody (4G10) and reprobing was
carried out using anti-Flag antibody.
Cloning and Transfection. NICE-4 protein (NP_055662),
RNA Binding Motif protein 10 isoform 1 (NP_05667), Far
upstream element-binding protein (NP_003893), and TRK-
Fused gene (NP_006061) were subcloned into a Flag epitope-
tagged mammalian expression vector, pCMVtag4A. 293T cells
were grown in 10 cm dishes. One dish transfected with wild-
type c-Src and pCMVtag4A vector as control; one was cotrans-
fected with wild-type c-Src and Flag-tagged cDNAs. The
expressed proteins were immunoprecipitated using anti-Flag
antibody, followed by SDS-PAGE and Western blotting. The
blots were probed with anti-phosphotyrosine antibody followed
by stripping and reprobing with anti-Flag antibodies.
In Vitro Kinase Assays Using GST-Fusion Proteins. Fusion
proteins were made using TNT-coupled rabbit reticulocyte
lysate system (Promega, Madison, WI) with the cDNAs cloned
in GST expression vector, PGEX4T1. The in vitro translated
GST-tagged proteins were puriﬁed with 10 µg of GST beads for
1 2ha t4°C. After incubation, the beads were washed two times
in lysis buffer and two times in kinase buffer (20 mM Hepes,
pH 7.4, 5 mM MgCl2, 2 mM MnCl2,5 0µM sodium vanadate,
50 µM DTT). Immune complexes were incubated for 30 min
at 30 °Ci n5µL of ATP mixture (10 µM cold ATP and 10 µCi of
[γ-
32P] ATP) and c-Src Kinase. Protein samples were then eluted
by boiling in sample buffer and resolved by SDS-PAGE. The
gel was dried and exposed to X-ray ﬁlm to visualize the
32P-
labeled protein bands.
PDGF Stimulation and Inhibition of Src Kinase. NIH3T3
cells were grown in DMEM containing 10% FBS supplemented
with antibiotics. For all PDGF stimulation experiments, cells
were stimulated with 100 ng/mL PDGF-BB for 5 min. For
inhibition of c-Src kinase, cells were treated with 2 µM c-Src
kinase inhibitor, SU6656, for 1 h prior to stimulation of cells
with PDGF-BB for 5 min.
In-Gel Trypsin Digestion and In-Solution Trypsin Diges-
tion. The silver-stained protein bands were excised and in-gel
trypsin digestion was performed as described previously.
15
Brieﬂy, the gel slices were excised and incubated with trypsin
overnight at 37 °C to allow digestion of proteins after a
reduction and alkylation step. After in-gel digestion, the tryptic
peptides were extracted. The supernatants from the in-gel and
in-solution trypsin digestion containing the peptide mixture
were partially dried down in a vacufuge to approximately 10
µL. For in-solution digestion and enrichment of phosphopep-
tides, phosphoscan kit was used according to manufacturer’s
prescribed conditions.
Liquid Chromatography-Mass Spectrometry. The extracted
peptide mixture was centrifuged for 2 min at 12 000g and 4 °C
and resolved by reversed-phase liquid chromatography on
Agilent 1100 Series LC system (Agilent Technologies, Palo Alto,
CA) equipped with a well plate sampler, a vacuum degasser,
and a capillary pump. Each fraction from the digested peptide
mixture was analyzed by automated nanoﬂow LC-MS/MS. An
Identiﬁcation of c-Src Kinase Substrates research articles
Journal of Proteome Research • Vol. 7, No. 9, 2008 3901Agilent Technologies 1100 series system was used to deliver a
ﬂow of 1.5 µL/min during desalting of the sample and 250 nL/
min during elution of the peptides into the mass spectrometer
as described before.
10 Each sample was loaded onto an online
analytical fused silica needle column (Proxion Biosystems,
Odense, Denmark) packed with 5-µm Vydac C18 resin. Washing
and desalting was done with 95% mobile phase A (H2O with
0.4% acetic acid and 0.005% heptaﬂuorobutyric (v/v)) and 5%
mobile phase B (90% acetonitrile, 0.4% acetic acid, 0.005%
heptaﬂuorobutyric acid in water). Samples were eluted from
the analytical column by a linear gradient of 90% mobile phase
A to 60% mobile phase A. A 34-min gradient was used for
elution. A potential of 2.8 kV was applied to the emitter (Proxion
Biosystems). The spectra were acquired on a quadrupole time-
of-ﬂight mass spectrometer (Q-TOF US-API, Micromass,
Manchester, U.K.) equipped with an ion source sample intro-
duction system designed by Proxeon Biosystems (Odense,
Denmark). Data were obtained in positive ion mode. Data-
dependent acquisition was performed with a ion mass window
to 2.5 Da. MS to MS/MS switch was set to a threshold of 10
counts/s, and MS/MS to MS was set to an intensity below a
threshold of 2 counts/s. Charge state recognition was used to
estimate the collision energy for the fragmented precursor. Scan
time was set to 0.9 s, and interscan time was set to 0.1 s. The
number of components (i.e., number of MS/MS per MS scan)
was set to three resulting in a total cycle time (one MS and
three MS/MS spectra) of 10 s. The acquisition of data was
performed using MassLynx (version 4.0). The parameters used
for generating peak lists from the raw data were the following:
smooth window, 4.00; number of smooth, 2; smooth mode,
Savitzky Golay; and percentage of peak height to calculate
centroid spectra, 80% with no baseline subtraction. The gener-
ated peak lists (pkl-ﬁle) were searched against the RefSeq
human protein database (build 33, 29 572 sequences) (ww-
w.ncbi.nlm.nih.gov./RefSeq/) using Mascot version 2.0, with a
mass accuracy of 1.1 Da for the parent ion (MS) and 0.2 for
the fragment ions (MS/MS), allowing a maximum of two missed
cleavages. Carbamidomethylation of cysteines was considered
as ﬁxed modiﬁcation, and oxidations of methionine residues,
“medium” arginine (+6 Da), “heavy” arginine (+10 Da), and
phosphorylation of tyrosine residue were considered as variable
modiﬁcations. An initial protein list was generated using the
following criteria. Only proteins containing at least one unique
peptide (if the sequence has not been assigned to a different
protein) with a Mascot score over 30 were considered in the
data set. The sequence of higher scoring peptides was manually
veriﬁed. Quantitation was performed on three to four peptides
(wherever available) by comparing the extracted ion chromato-
gram of the corresponding light and heavy peptides using MS-
Quant.
16 Reproducibility of measurements was performed by
using two analysis of variance models as described earlier.
17
The tandem mass spectra were manually veriﬁed to assign the
sequence and phosphorylation sites for all peptides identiﬁed
in this study (Supplementary Table 1). The phosphorylation
sites were manually veriﬁed and assigned after conﬁrmation
of a mass difference of 243 Da corresponding to phosphoty-
rosine residue.
Peptide Microarrays and Data Analysis. The WT (peptides
containing a tyrosine residue in the center) and MUT (peptides
where the central tyrosine residue was replaced by phenyla-
lanine) peptides (Supplementary Table 2) were each spotted
as triplicates on glass slides (Pepscan Systems, Lelystad,
Netherlands) as described earlier.
18 c-Src kinase assays were
carried out using these custom peptide microarrays by incu-
bating 50 ng of recombinant c-Src Kinase (Invitrogen, Carlsbad,
CA) in kinase reaction buffer and 300 µCi/ml γ
33P-labeled ATP
(AH9968; GE Healthcare Biosciences Corp., Piscataway, NJ) at
25 °Cf o r1hi na1 2 0µL reaction volume supplemented with
200 µM ATP. The reaction was stopped and the following
washing steps were performed: 2 washes in 2 M sodium
chloride containing 1% Triton X-100 followed by 3 washes in
phosphate buffered saline containing Triton X-100 and 1 wash
in distilled water. The glass slides were then air-dried and
exposed to the phosphorimager screen for 12 h and scanned
using Biorad Molecular Imager FX (Bio-Rad Laboratories, Inc.,
Hercules, CA). The image was processed using GenePix Pro 6.0
software (Molecular Devices Corporation, Sunnyvale, CA).
Autoradiographs were obtained using a phosphorimager screen.
The assay was performed in triplicate. The intensity values
obtained were transformed to the log base 2 scale. Effects on
intensity due to the position of the spot on the slide were
estimated by performing a local regression analysis (loess) with
respect to chip coordinates, and subtracted out.
19 Normalized
log 2 intensities for triplicate spots were averaged, and the
mean log 2 MUT intensity was subtracted from the corre-
sponding mean log 2 WT intensity for each peptide. The
resulting background adjusted values were averaged over
replicate arrays. The mean background adjusted log intensity
for each peptide on the Y-axis, and the average of WT, and
MUT log intensities on the X-axis were plotted to estimate the
distribution of the intensity values arising from the phospho-
rylated peptides. A key assumption for selection of positive
(phosphorylated) peptides is that WT peptide intensity values
are greater than MUT peptide intensities. It is also assumed
that higher intensity peptides are more likely to be positive.
We note that, consistent with this assumption, the WT intensity
is consistently higher than MUT intensity for the high intensity
peptides on the right side of the plot. Likewise, there is greater
symmetry on the left side quadrant of the MvA plot, where we
expect nonphosphorylated peptides to have WT intensities that
are as likely to be lower than MUT values as higher. The
classical False Positive Rate (expected error rate for a set of
points) is derived by evaluating symmetry in the Y-axis. For
each value of A, the classical FPR blue curve gives: (number of
points below the X-axis to the right of A)/(number of points
above the X-axis to the right of A), and describes the expected
number of false positives in the upper right quadrant of the
plot. Sometimes it is desirable to estimate the probability that
a single given point is a false positive, allowing us to move the
threshold to the left until the price of adding one more peptide
is too high. This is described by the local false positive rate
curve. The local FPR curve gives the probability of a positive
peptide located at A being a false positive. We selected all
peptides where the local false positive rate was lower than 0.15
and WT intensities were 2-fold greater compared to MUT. The
resulting set has an overall FPR of 0.085.
Results and Discussion
Stable Isotope Labeling of Cellular Proteins for the Iden-
tiﬁcation of c-Src Kinase Substrates. SILAC involves metabolic
labeling of cellular proteomes by growing the cells in media
containing amino acids labeled with stable isotopes. SILAC
enables identiﬁcation of peptides labeled in vivo and relative
quantitation of abundance of the peptides arising out of a
mixture of labeled and unlabeled protein samples.
15 This
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in immunoprecipitates that arise due to nonspeciﬁc binding.
Because of the complexity of cell lysates, and because kinase
substrates generally exhibit low stoichiometry of tyrosine
phosphorylation, speciﬁc identiﬁcation of tyrosine kinase
substrates can be facilitated by prior enrichment of tyrosine-
phosphorylated proteins with anti-phosphotyrosine antibodies.
We applied SILAC for the identiﬁcation of the c-Src kinase
substrates in human embryonic kidney cells by overexpression
of a constitutively active form of c-Src followed by afﬁnity
puriﬁcation of tyrosine-phosphorylated proteins. We transiently
overexpressed either a kinase inactive c-Src (K298M) as a
control or a constitutively active c-Src (Y527F) kinase in 293T
cells. Phosphorylation of the C-terminal tyrosine by C-terminal
Src Kinase (CSK) allows inactivation of c-Src.
20–22 Hence,
mutation of this tyrosine residue to phenylalanine allows c-Src
kinase to be constitutively active by preventing its folding and
by allowing the kinase domain access to its substrates.
23,24
Inhibition of c-Src activity is often achieved by coexpression
of the c-Src-inactivating C-terminal Src Kinase (CSK), the
kinase-inactive Src mutant Src K298 M,
25 or by treatment of
the cells with c-Src inhibitors.
Three populations of human embryonic kidney cells were
grown in DMEM containing
12C6-arginine (light),
13C6-arginine
(medium) and
13C6-
15N4-arginine (heavy), respectively (Figure
1). The cells grown in light medium were transfected with a
kinase inactive c-Src as a negative control.
26 Cells grown in
medium and heavy isotope containing media were transfected
with a constitutively active form of c-Src (Y527F) and harvested
at 12 or 24 h post-transfection, respectively. We found an
increased tyrosine phosphorylation upon transfection of con-
stitutively active form of c-Src for 24 h (Figure 2). We have also
observed that the Y416 in c-Src gets phosphorylated more in
this state which points to the increased c-Src tyrosine kinase
activity (Figure 2). In addition, the trend of increasing tyrosine
phosphorylation could also serve as one more surrogate
signature of substrates as one would expect the phosphoryla-
tion level to increase during this time course.
Mixing of light, medium and heavy isotope labeled cell
lysates allowed us to compare the proﬁle of proteins in a single
MS experiment. In MS/MS spectra, fragmentation patterns
generated by light, medium and heavy peptide pairs are
identical except for the expected mass shift of the fragment
ions. The ratio of the intensity of the heavier versus the light
peptides provides information about the degree of phospho-
rylation of a protein and hence its enrichment upon expression
of an active c-Src kinase. Thus, the greater the extent of
phosphorylation of a protein by c-Src kinase, the higher should
be its abundance in anti-phosphotyrosine antibody immuno-
precipitates. Peptide sets with a little or no increase in intensity
indicate that the protein is not different in abundance in the
different states being compared. Such proteins were not
investigated further as they are likely nonspeciﬁcally bound
proteins. An increase in heavy/light intensity ratio, indicating
an increase in total phosphotyrosine content upon Src kinase
expression and activity, was found in peptides derived from
36 proteins (Tables 1 and 2). Of these, 10 proteins were either
known Src family kinase substrates or proteins known to
interact with Src family kinases (Table 1), whereas the remain-
ing 26 proteins have not previously been described as sub-
strates of c-Src or Src family members (Table 2) in higher
eukaryotes. The known substrates identiﬁed in this screen
included EWS1 (Ewing sarcoma breakpoint region 1),
27 cort-
actin,
28 calponin-3,
29 hnRNP-K (Heterogeneous nuclear ribo-
nucleoprotein K),
30,31 G3BP (RasGAP SH3-domain binding
protein)
32–34 and c-Src itself.
35 The protein with maximum
increase in tyrosine phosphorylation upon c-Src overexpression
was c-Src itself. Other known and novel Src family substrates
displayed >2-fold increase in intensity of phosphorylation.
Apart from signaling and cytoskeletal proteins, we also identi-
ﬁed DNA and RNA binding proteins in our analysis. Some of
the reasons it is not possible in a kinase-substrate identiﬁca-
tion screen of this type to possibly identify every known
substrate are (i) previously described substrates might not be
expressed in the cell line that we have used; (ii) although the
substrates might be expressed, they might not be abundant
enough to be enriched and detected in our experiments; (iii)
the phosphorylation might not occur or occur at a lower level
in the cells that we have used; and (iv) the time course and
kinetics of phosphorylation in the system that we have em-
ployed might be different from the systems previously used in
the literature to describe substrates. Thus, although it is not
possible to identify all of the known substrates of Src, identi-
ﬁcation of 6 known substrates of Src along with validation of
some novel ones is indicative of the success of this type of
phosphoproteomic screen.
We performed relative quantitation of tyrosine phosphory-
lation for each protein as a measure of increase in intensity
ratios from light isotope to heavier isotope containing peptides
(Supplementary Table 1). Figure 3 shows representative MS
spectra for six of the proteins identiﬁed from our screen. In
addition to identiﬁcation of proteins with increased phospho-
rylation and quantitation, we also mapped 6 phosphorylation
sites; Y334 in cortactin
10 (Figure 4A) and Y72 in hnRNP-K
30
Figure 1. (A) Schematic for the integrated proteomic approach
for the identiﬁcation of c-Src kinase substrates. Human embry-
onic kidney (HEK) 293T cells growing in Arg ‘0’ containing
medium were transiently transfected with a kinase-dead Src
(K298M) and 293T cells growing in Arg ‘6’ and Arg ‘10’ were
transiently transfected with constitutively active Src kinase
(Y527F). Arg ‘0’ refers to
12C6-arginine, Arg ‘6’ refers to
13C6-
arginine and Arg ‘10’ refers to
13C6-
15N4-arginine, isotopic labeled
forms of arginine used to differentially label 293T cells for
identiﬁcation of Src substrates.
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also identiﬁed 4 novel tyrosine phosphorylation sites on each
on EWS1 (Figure 4C), FUSE-binding protein 1 (Figure 4D),
calponin-3 (Figure 4E) and FIP1-like1 (Figure 4F). We note that,
although EWS1 was a known c-Src substrate, no tyrosine
phosphorylation sites were previously localized.
One of the drawbacks of our experiments is that lysine was
not available as 3 different isotopic forms at the time we
initiated our experiments. By using 3 isotopes of lysine along
with arginine, we would have obtained a better peptide
coverage for each protein and likely identiﬁed additional
proteins as substrates of c-Src. Nevertheless, we performed a
lysine and arginine labeled SILAC experiment in a similar
manner but followed by enrichment of phosphopeptides using
antibodies against phosphotyrosine to see if we could identify
phosphorylated peptides, but unfortunately, we could only
identify 8 tyrosine phosphorylation sites (data not shown). We
do not know the reasons for such a low yield. However, a
protein IP serves our purpose of identifying the proteins that
are substrates of Src even though the site is still not identiﬁed.
This is the reason we coupled our approach with peptide
microarrays to aid in identiﬁcation of phosphopeptides.
Validation of a Subset of Novel c-Src Substrates. Further
validation of the proteins identiﬁed by SILAC to prove that they
are bona ﬁde substrates usually involves the use of antibodies
against these proteins. The validation of all of the protein
candidates is not always possible, especially for novel proteins,
as it depends on the availability of good antibodies. As
commercial antibodies were not available for many of the
proteins identiﬁed, we chose to investigate a subset of proteins,
if they were direct substrates of c-Src using in vitro kinase
assays. We selected NICE-4, RBM10, FBP1 and TRK-fused gene
for this purpose, as their cDNAs were readily available. We used
rabbit reticulocytes to perform in vitro transcription and
Figure 2. Tyrosine phosphorylation proﬁle of proteins on transfection with inactive and active forms of c-Src. 293T cells were transfected
with inactive and active forms of c-Src, cells were lysed, and tyrosine-phosphorylated proteins were immunoprecipitated from the cell
lysates as described in Experimental Procedures. Cell lysates and immunoprecipitates were then run on a 10% SDS-PAGE and transferred
to nitrocellulose membranes. The membranes were probed with anti-phosphotyrosine antibodies and reprobed with phospho (Y416)-
Src antibody.
Table 1. Known Src Family Kinase Substrates and Interactors Identiﬁed in This Study by Overexpression of c-Src Kinase in 293T
Cells Followed by SILAC
NCBI accession no. protein fold increase (heavy/light)
a ( SD Reference
Known c-Src Substrates
1 NP_005408 c-Src 30 ( 9.1 35
2 NP_005222 Cortactin 4.9 ( 2.6 28
3 NP_005234 Ewing sarcoma breakpoint region 1 4.6 27
4 NP_112552 Heterogeneous nuclear ribonucleoprotein K 3.7 ( 0.2 30, 31
5 NP_001830 Calponin 3 3.4 29
6 NP_005745 RasGAP SH3-domain binding protein 2.2 32–34
Known Src Family Kinase Interactors
7 NP_112533 Heterogeneous nuclear ribonucleoprotein A2/B1 10.2 ( 5.1 45
8 NP_002129 Heterogeneous nuclear ribonucleoprotein D 4.3 45
9 NP_006833 Splicing factor 3B subunit 2 5.6 ( 0.9 46
10 NP_005511 Heterogeneous nuclear ribonucleoprotein H1 3.0 45
a Heavy refers to Arg ‘10’ and light refers to Arg ‘0’ containing peptides.
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bated along with c-Src kinase to investigate if it could phos-
phorylate these proteins. After incubation with c-Src kinase,
the proteins were resolved by SDS-PAGE and autoradiographs
were obtained. We found that all of the tested proteins were
tyrosine phosphorylated upon incubation with c-Src kinase
(Figure 5A). TRK-fused gene from Xenopus laevis has been
shown to interact with SH3 domains of various proteins
including v-Src but did not bind to neuronal speciﬁc Src in
vitro.
36
We veriﬁed if the above c-Src substrates were also substrates
of c-Src in vivo by cotransfecting these proteins with wild-type
c-Src in 293T cells. We also subcloned these cDNAs into a Flag
epitope-tagged vector, pCMVtag4A, and cotransfected 293T
cells with wild-type c-Src kinase or with an empty vector. The
proteins were immunoprecipitated using anti-Flag antibodies,
resolved by SDS-PAGE, and immunoblotted with anti-phos-
photyrosine antibodies. Upon cotransfection with c-Src kinase,
we again observed increased tyrosine phosphorylation of all
the tested proteins suggesting that these proteins were also in
vivo substrates of c-Src (Figure 5B). We have previously
identiﬁed NICE-4 as a tyrosine-phosphorylated protein in a
global phosphoproteomic study of HeLa cells.
10 RBM10, FBP1
and TRK-fused gene are novel tyrosine-phosphorylated proteins
and further investigations need to be carried out to determine
how they transduce signals downstream of c-Src kinase and if
tyrosine phosphorylation regulates this process.
Involvement of a Subset of Novel Substrates in Platelet-
Derived Growth Factor Signaling. Since kinase activity of c-Src
is required for modulating cellular responses to PDGF receptor
stimulation,
37 we chose to study the role of a subset of novel
substrates in PDGF signaling. The role of c-Src has been well-
studied in PDGF signaling.
38 We investigated the involvement
of EWS1, BTF and RBM10 in PDGF receptor signaling. Cortactin
and p130CAS were used as positive controls. For this experi-
ment, NIH3T3 cells, which express endogenous PDGF recep-
tors, were treated with PDGF-BB in the presence or absence
of a c-Src kinase inhibitor, SU6656 (2-oxo-3-(4,5,6,7-tetrahy-
dro-1 H-indol-2-ylmethylene)-2,3-dihydro-1H-indole-5-sulfonic
acid dimethylamide).
38 By activating PDGF signaling in NIH3T3
cells, we investigated the ability of these proteins to get
tyrosine-phosphorylated upon ligand-induced stimulation of
the PDGF receptor. We found that all of the novel proteins were
tyrosine-phosphorylated upon stimulation of PDGF receptor
(Figure 5C), as was the case with the two known substrates.
Using SU6656, a potent inhibitor of c-Src kinase, we have
shown the involvement of three novel proteins RBM10, EWS1
and BTF as c-Src substrates in PDGF signaling (Figure 5C). c-Src
has been shown to have been involved in the regulation of
nuclear proteins and transcription factors downstream of PDGF
signaling and plays an important role in controlling DNA
synthesis.
39 We have also examined the involvement of RasGAP
SH3-domain binding protein and Thyroid hormone receptor
associated protein 3 in PDGF signaling using SU6656 but could
not detect any tyrosine phosphorylation of these proteins in
any state (data not shown). Further experiments need to be
done in order to examine the precise role of these proteins and
the importance of their phosphorylation in PDGF signaling.
One important caveat of these experiments using SU6656 for
inhibition of Src kinase is that it could bind and inhibit other
related kinases. When better inhibitors become available, this
would be a great approach to identify the kinase-substrate
relationships.
Ewing sarcoma breakpoint region 1 (EWS1) is an RNA
binding protein and has been shown to be involved in gene
translocations and often appear as fusion of EWS with ETS
family transcription factor genes and known to cause Ewing
sarcoma tumors.
40 One of the fusion proteins EWS-Fli1 has
been implicated in insulin-like growth factor 1 (IGF-1)
41 as well
as PDGF-BB
42 induced proliferation of Ewing sarcoma cells.
The implication of EWS1 as a downstream substrate of c-Src
in PDGF-signaling might shed light into the mechanism of
induction of proliferation by these genes in signaling and
tumors. Bcl-2-associated transcription factor 1 (BTF) is an
Table 2. List of Novel Potential Src Substrates Identiﬁed Using SILAC by Overexpression of Src Kinase in 293T Cells
accession no. protein fold increase (heavy/light)
a ( SD
NP_005454 Heterogeneous nuclear ribonucleoprotein D-like 10.0 ( 5.2
NP_113680 RNA binding motif protein 4B 9.4 ( 3.7
NP_003760 Splicing factor, arginine/serine-rich 9 9.3 ( 3.6
NP_004490 Heterogeneous nuclear ribonucleoprotein AB 8.0
NP_005667 RNA binding motif protein 10 7.2 ( 0.6
NP_003893 FUSE binding protein 6.9 ( 0.8
NP_055662 NICE-4 6.6 ( 2.1
NP_919223 Heterogeneous nuclear ribonucleoprotein A3 6.1 ( 2.5
NP_003676 FUSE binding protein 2 5.7 ( 2.2
NP_004951 FUS/TLS oncogene 5.0 ( 0.9
NP_005849 A-kinase anchor protein 8 5.5
NP_055554 Bcl-2-associated transcription factor 1 5.5
NP_877952 Arsenate resistance protein ARS2 5.4
NP_473357 FUS interacting protein (serine/arginine-rich) 1 5.1
NP_005110 Thyroid hormone receptor associated protein 3 5.1
NP_008937 Cleavage and polyadenylation speciﬁc factor 5 4.8 ( 3.1
XP_028253 Similar to Zinc ﬁnger CCCH-type domain-containing protein 6 3.8 ( 1.9
NP_079222 NEFA-interacting nuclear protein 3.8 ( 0.8
NP_060082 Zinc ﬁnger, CCHC domain containing 8 3.7
NP_005057 Splicing factor proline/glutamine-rich 3.1 ( 1.0
NP_005780 Proteasome activator subunit 3 2.6 ( 0.4
NP_006061 TRK-fused gene 2.4
NP_003746 Eukaryotic translation initiation factor 3, subunit 4 2.2
NP_663760 Ataxin 2 related protein 2.2
NP_067038 Chromosome 20 open reading frame 77 2.0 ( 0.3
NP_057123 Homeobox prox 1 2.0 ( 0.3
a Heavy refers to Arg ‘10’ and light refers to Arg ‘0’ containing peptides.
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43 localized to the nucleus,
whose function is still under investigation. RNA binding motif
10 (RBM10) is an RNA binding protein with a zinc ﬁnger
domain, associated with the expression of Bax family members
in breast cancers and VEGF.
44 This was the ﬁrst time BTF and
RBM10 were identiﬁed as a tyrosine-phosphorylated proteins
and the ﬁnding that they are components of PDGF signaling
downstream of c-Src might help to understand the role of BTF
and RBM10 in growth factor receptor signaling. Although we
have observed tyrosine phosphorylation of a subset of proteins
in PDGF signaling, it is not possible to validate all candidates
in any proteomics experiment because of the following reasons:
(i) Availability of good immunoprecipitating antibodies against
these proteins is limited, and hence, we have tagged a subset
of these proteins to show that these are indeed substrates; and
(ii) To validate these proteins in a speciﬁc signaling pathway,
it is not easy to predict in which signaling pathway(s) these
proteins are involved downstream of c-Src. However, studies
are currently in progress on a subset of proteins to show their
physiological relevance and also to identify tyrosine-phospho-
rylated proteins in growth factor signaling pathways down-
stream of Src kinase.
Development of Peptide Microarrays for High-Throughput
Validation of c-Src Substrates. Although we have established
above that a number of novel proteins are potential substrates
of c-Src, the exact residues that undergo phosphorylation have
not been identiﬁed in most of these instances. Hence, we
developed a custom peptide microarray as a platform to rapidly
Figure 3. MS spectra of 6 proteins identiﬁed as Src substrates by SILAC. The 3 spectral peaks in each ﬁgure represent the mass shift
of the same peptide. The relative increase in intensity ratios between light to heavy are represented below in parentheses. (A) A
doubly charged peptide from cortactin (1:7); (B) a triply charged peptide from NICE-4 (1:7); (C) a doubly charged peptide from Bcl2-
associated transcription factor (1:7.5); (D) a doubly charged peptide from FUSE-binding protein 1 (1:8); (E) a doubly charged peptide
from FUSE-binding protein 2 (1:4); (F) a doubly charged peptide from RNA binding motif 10 (1:7.5).
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phosphorylated by c-Src. We systematically designed 312
peptides encompassing all tyrosines from 14 selected proteins
(Table 3). These were synthesized in such a fashion that they
contained the tyrosine residue being tested in the center. In
parallel, an equal number of peptides that have the centric
tyrosine residues mutated to phenylalanine were designed.
In all, 624 WT or mutant (312 WT and 312 MUT) peptides from
14 proteins were spotted with each sequence being represented
in triplicate, on to the glass slides as described earlier.
18 The design
of these peptide microarrays is analogous to DNA microarrays
manufactured by Affymetrix for mRNA expression studies. c-Src
kinase assays were performed on the peptide microarrays and
the arrays subsequently exposed to phosphorimager screen
Figure 4. MS/MS spectra of novel phosphorylation sites identiﬁed in this study. (A) Phosphopeptide NASTFEDVTQVSSApYQK derived
from Cortactin; (B) phosphopeptide TDpYNASVSVPDSSGPER derived from hnRNPK; (C) phosphopeptide QDHPSSMGVpYGQESGG-
FSGPGENR derived from Ewing sarcoma breakpoint region 1; (D) phosphopeptide IGGDAGTSLNSNDpYGYGGQK derived from FUSE-
binding protein 1; (E) phosphopeptide GPSpYGLSAEVK derived from Calponin-3; (F) phosphopeptide TGAPQpYGSYGTAPVNLNIK
derived from FIP1-like 1.
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as described under Experimental Procedures. We normalized the
intensity values and compared the log 2 intensities of the WT
peptides against their corresponding MUT peptides. The intensity
values from 3 different experiments were averaged individually
for WT and MUT peptides and plotted (Figure 5B). The spots in
the upper right quadrant were taken as true positives (Figure 6B).
The false positive rates (FPR) were calculated by assuming that
those peptides for which MUT intensity exceeded WT intensity
were not phosphorylated, and that the variation of WT-MUT
intensities for those points was representative of nonphosphory-
lated peptides (Figure 6C). On the basis of the calculated FPRs, a
line was drawn which separates the true positives from the
remainder of the peptides.
From this analysis, we have identiﬁed phosphorylation sites
on 12 out of 14 proteins that were spotted on peptide microarrays.
Peptides containing multiple tyrosines were mutated systemati-
cally and all the tyrosine containing peptides were looked at along
with their corresponding mutated counterparts to deduce the
correct phosphorylated peptide. A total of 34 peptides from 12
proteins (Table 3) out of 312 peptides from 14 proteins spotted
(Supplementary Table 2) were phosphorylated by c-Src in our
analysis. This included 6 phosphopeptides from Bcl2-associated
transcription factor, 5 from Thyroid hormone receptor associated
protein 3, and 4 phosphopeptides from ARS2. We did not detect
phosphorylation on any of the peptides derived from two proteins,
Zinc ﬁnger, CCHC domain containing 8 and Splicing factor
proline/glutamine-rich. Thus, peptide arrays allowed assignment
of phosphorylation sites in a high-throughput fashion and also
served as an additional validation step for potential substrates
identiﬁed from our SILAC experiments. Because of the tremen-
dous potential and promise that peptide microarrays hold for the
identiﬁcation kinase-substrate identiﬁcation, studies are ongoing
to spot the peptides from other proteins identiﬁed in this and
other mass spectrometry based studies to identify the kinase-
speciﬁc phosphorylation sites and build phosphorylation motifs.
Conclusions
This study describes identiﬁcation of substrates of a nonre-
ceptor tyrosine kinase using a combination of proteomic
Figure 5. Experimental validation of tyrosine phosphorylation of
proteins obtained from c-Src kinase overexpression in 293T cells.
(A) In vitro kinase assays using GST tagged proteins and c-Src
using a rabbit reticulocyte in vitro transcription and translation
system. (B) 293T cells were cotransfected with genes of interest
along with either empty vector PCMVtag4A or with c-Src. Culture
media was changed 12 h after transfection and cells were serum-
starved for 12 h and lysed 48 h after transfection. Proteins were
immunoprecipitated using anti-Flag antibodies and Western
blotting was performed using phosphotyrosine antibodies and
reprobed. (C) Validation of a subset of proteins in PDGF signaling.
NIH3T3 cells have been grown to conﬂuence and serum-starved
for 12 h followed by stimulation with PDGF-BB (100 ng/mL for 5
min) and PDGF stimulation after treatment with SU6656 (2 µM
for 1 h prior to lysis or stimulation), and cell lysates were
subjected to immunoprecipitation using anti-phosphotyrosine
antibodies, probed with respective antibodies, and reprobed in
whole cell lysates.
Table 3. Peptides from the Newly Identiﬁed Src Substrates
That Were Phosphorylated by c-Src on Peptide Microarrays
accession no. protein phosphopeptide
1 NP_003893 FUSE binding protein 1 1. EVRNEYGSRIG
2. RQQAAYYAQTS
2 NP_003676 FUSE binding protein 2 1. GDRNEYGSRIG
2. AYYSHYYQQPP
3. RQQAAYYGQTP
3 NP_055554 BCL2-associated transcription
factor 1
1. YHRGGYRPVWN
2. EETEDYRQFRK
3. GRGRGYYQGGG
4. NGSSRYSPSQN
5. RGRGYYQGGGG
6. RSSSPYSKSPV
4 NP_005667 RNA binding motif protein 10 1. ARGSSYGVTST
2. EPPVDYSYYQQ
3. DRTGRYGATDR
5 NP_006061 TRK-fused Gene 1. NEDITYDELVL
2. QMYQQYQQQAG
6 NP_005745 RasGAP SH3-domain-binding
protein
1. NDIFRYQDEVF
7 NP_663760 Ataxin 2 related protein 1. GQQGKYRGAKG
8 NP_005849 A-Kinase anchor protein 8 1. RPSYSYDYEFD
9 NP_005110 Thyroid hormone receptor
associated protein 3
1. NYRQAYSPRRG
2. NHPRVYQNRDF
3. SGGAAYTKRYL
4. GGYGNYRSNWQ
5. GTPAGYGRGRE
10 NP_877952 Arsenate resistance protein
ARS2
1. AGRGNYDAFRG
2. QGLMPYGQPRP
3. HSSDPYHSGYE
4. KRYNDYKLDFR
11 NP_006833 Splicing factor 3B subunit 2 1. HGDLYYEGKEF
2. EEPEIYEPNFI
3. QREESYSRMGY
12 NP_055983 hypothetical protein LOC23211 1. GRGRGYRGRGS
2. DRYNSYNRPRP
3. RKYREYSPPYA
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3908 Journal of Proteome Research • Vol. 7, No. 9, 2008approaches. Use of SILAC methodology allowed us to identify
a number of known and novel substrates of c-Src in human
embryonic kidney 293T cells. We identiﬁed 4 new phospho-
rylation sites and also validated a subset of the novel substrates
as direct c-Src substrates using in vitro kinase assays. We
corroborated our results for four proteins as direct substrates
of c-Src. We also implicated three of the novel c-Src substrates
as tyrosine-phosphorylated proteins in PDGF receptor signal-
ing. Since identiﬁcation of phosphopeptides is still a challenge
in proteomics, we designed a custom peptide microarray
platform for high-throughput identiﬁcation of peptides phos-
phorylated by speciﬁc kinase, c-Src, in this case.
Using peptide microarrays, we identiﬁed 34 phosphopep-
tides phosphorylated by c-Src that are derived from 12 novel
candidate substrate proteins that were identiﬁed by SILAC as
potential c-Src substrates. Identiﬁcation of the phosphopep-
tides from these 12 new substrates also provides validation of
this approach. It is worth noting here that most tyrosine
containing peptides were not phosphorylated by c-Src. Peptide
microarray technology has its own limitations. Although it can
help identify bona ﬁde substrate peptides in many instances,
it is possible that some sequences that are phosphorylated in
vivo do not get phosphorylated because of lack of secondary
and tertiary structure of the immobilized peptides. Further,
although the peptide microarray analysis has shed light on the
phosphopeptides preferentially phosphorylated by c-Src, these
sites still remain to be investigated in vivo using other
methodologies.
The present study offers many encouraging leads, such as
the identiﬁcation of tyrosine phosphorylation of a subset of
new c-Src substrates that are components in the PDGF signal-
ing downstream of c-Src. Clearly, further characterization of
these novel sites and proteins will result in a signiﬁcant
expansion of our knowledge of the c-Src kinase signaling
network. The signiﬁcance of tyrosine phosphorylation on each
of the newly discovered sites remains to be determined. In any
case, these results demonstrate that c-Src-mediated tyrosine
phosphorylation is extensive and implicates a number of
hitherto unrecognized proteins as c-Src kinase substrates.
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